Evaluation strategies for measuring pneumococcal conjugate vaccine impact in low-resource settings
Objectives: Pneumococcal conjugate vaccines (PCVs) are effective in reducing pneumococcal disease. We measured 13-valent PCV (PCV13) effect on different pneumococcal outcomes using diverse studies in Lao People’s Democratic Republic. Methods: Studies included: pre-PCV13 population-based record revie...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Taylor and Francis
2021
|
| _version_ | 1797108727370743808 |
|---|---|
| author | von Mollendorf, C Lim, R Choummanivong, M Sychareun, V Vilivong, K Lai, JYR Chan, J Dunne, EM Phommachanh, S Moore, KA Ortika, BD Gray, A Weaver, R Mayxay, M Phetsouvanh, R Datta, SS Fox, K Newton, PN Mulholland, KE Nguyen, CD Dance, DAB Satzke, C Russell, FM |
| author_facet | von Mollendorf, C Lim, R Choummanivong, M Sychareun, V Vilivong, K Lai, JYR Chan, J Dunne, EM Phommachanh, S Moore, KA Ortika, BD Gray, A Weaver, R Mayxay, M Phetsouvanh, R Datta, SS Fox, K Newton, PN Mulholland, KE Nguyen, CD Dance, DAB Satzke, C Russell, FM |
| author_sort | von Mollendorf, C |
| collection | OXFORD |
| description | Objectives: Pneumococcal conjugate vaccines (PCVs) are effective in reducing pneumococcal disease. We measured 13-valent PCV (PCV13) effect on different pneumococcal outcomes using diverse studies in Lao People’s Democratic Republic. Methods: Studies included: pre-PCV13 population-based record review of hospitalized childhood pneumonia cases; acute respiratory infection (ARI) study post-PCV13 to demonstrate effectiveness (VE) against hypoxic pneumonia; invasive pneumococcal disease (IPD) surveillance in all ages (2004–2018); carriage studies in children hospitalized with ARI (2013–2019); community carriage surveys pre- and post-PCV13. Results: Annual pneumonia incidence rate in children pre-PCV13 was 1,530 (95% confidence interval [CI] 1,477–1,584) per 100,000. Adjusted VE against hypoxic pneumonia was 37% (95% CI 6–57%). For IPD, 85% (11/13) of cases were due to vaccine-types pre-PCV13, and 43% (3/7) post-PCV13 in children aged <5 years; for ≥5 years, 61% (27/44) and 42% (17/40), respectively. For ARI cases, adjusted VE for vaccine-type carriage was 39% (95% CI 4–60) in <5 year olds; slightly higher than community surveys (23% [95% CI 4–39%] in 12–23 month olds). Conclusions: Despite limited baseline data, we found evidence of PCV13 impact on disease and carriage. Our approach could be used in similar settings to augment existing WHO PCV evaluation guidelines. |
| first_indexed | 2024-03-07T07:31:10Z |
| format | Journal article |
| id | oxford-uuid:f1d8d145-8d9a-4e7c-b9b2-4d23fca69672 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:31:10Z |
| publishDate | 2021 |
| publisher | Taylor and Francis |
| record_format | dspace |
| spelling | oxford-uuid:f1d8d145-8d9a-4e7c-b9b2-4d23fca696722023-01-17T10:51:49ZEvaluation strategies for measuring pneumococcal conjugate vaccine impact in low-resource settingsJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:f1d8d145-8d9a-4e7c-b9b2-4d23fca69672EnglishSymplectic ElementsTaylor and Francis2021von Mollendorf, CLim, RChoummanivong, MSychareun, VVilivong, KLai, JYRChan, JDunne, EMPhommachanh, SMoore, KAOrtika, BDGray, AWeaver, RMayxay, MPhetsouvanh, RDatta, SSFox, KNewton, PNMulholland, KENguyen, CDDance, DABSatzke, CRussell, FMObjectives: Pneumococcal conjugate vaccines (PCVs) are effective in reducing pneumococcal disease. We measured 13-valent PCV (PCV13) effect on different pneumococcal outcomes using diverse studies in Lao People’s Democratic Republic. Methods: Studies included: pre-PCV13 population-based record review of hospitalized childhood pneumonia cases; acute respiratory infection (ARI) study post-PCV13 to demonstrate effectiveness (VE) against hypoxic pneumonia; invasive pneumococcal disease (IPD) surveillance in all ages (2004–2018); carriage studies in children hospitalized with ARI (2013–2019); community carriage surveys pre- and post-PCV13. Results: Annual pneumonia incidence rate in children pre-PCV13 was 1,530 (95% confidence interval [CI] 1,477–1,584) per 100,000. Adjusted VE against hypoxic pneumonia was 37% (95% CI 6–57%). For IPD, 85% (11/13) of cases were due to vaccine-types pre-PCV13, and 43% (3/7) post-PCV13 in children aged <5 years; for ≥5 years, 61% (27/44) and 42% (17/40), respectively. For ARI cases, adjusted VE for vaccine-type carriage was 39% (95% CI 4–60) in <5 year olds; slightly higher than community surveys (23% [95% CI 4–39%] in 12–23 month olds). Conclusions: Despite limited baseline data, we found evidence of PCV13 impact on disease and carriage. Our approach could be used in similar settings to augment existing WHO PCV evaluation guidelines. |
| spellingShingle | von Mollendorf, C Lim, R Choummanivong, M Sychareun, V Vilivong, K Lai, JYR Chan, J Dunne, EM Phommachanh, S Moore, KA Ortika, BD Gray, A Weaver, R Mayxay, M Phetsouvanh, R Datta, SS Fox, K Newton, PN Mulholland, KE Nguyen, CD Dance, DAB Satzke, C Russell, FM Evaluation strategies for measuring pneumococcal conjugate vaccine impact in low-resource settings |
| title | Evaluation strategies for measuring pneumococcal conjugate vaccine impact in low-resource settings |
| title_full | Evaluation strategies for measuring pneumococcal conjugate vaccine impact in low-resource settings |
| title_fullStr | Evaluation strategies for measuring pneumococcal conjugate vaccine impact in low-resource settings |
| title_full_unstemmed | Evaluation strategies for measuring pneumococcal conjugate vaccine impact in low-resource settings |
| title_short | Evaluation strategies for measuring pneumococcal conjugate vaccine impact in low-resource settings |
| title_sort | evaluation strategies for measuring pneumococcal conjugate vaccine impact in low resource settings |
| work_keys_str_mv | AT vonmollendorfc evaluationstrategiesformeasuringpneumococcalconjugatevaccineimpactinlowresourcesettings AT limr evaluationstrategiesformeasuringpneumococcalconjugatevaccineimpactinlowresourcesettings AT choummanivongm evaluationstrategiesformeasuringpneumococcalconjugatevaccineimpactinlowresourcesettings AT sychareunv evaluationstrategiesformeasuringpneumococcalconjugatevaccineimpactinlowresourcesettings AT vilivongk evaluationstrategiesformeasuringpneumococcalconjugatevaccineimpactinlowresourcesettings AT laijyr evaluationstrategiesformeasuringpneumococcalconjugatevaccineimpactinlowresourcesettings AT chanj evaluationstrategiesformeasuringpneumococcalconjugatevaccineimpactinlowresourcesettings AT dunneem evaluationstrategiesformeasuringpneumococcalconjugatevaccineimpactinlowresourcesettings AT phommachanhs evaluationstrategiesformeasuringpneumococcalconjugatevaccineimpactinlowresourcesettings AT mooreka evaluationstrategiesformeasuringpneumococcalconjugatevaccineimpactinlowresourcesettings AT ortikabd evaluationstrategiesformeasuringpneumococcalconjugatevaccineimpactinlowresourcesettings AT graya evaluationstrategiesformeasuringpneumococcalconjugatevaccineimpactinlowresourcesettings AT weaverr evaluationstrategiesformeasuringpneumococcalconjugatevaccineimpactinlowresourcesettings AT mayxaym evaluationstrategiesformeasuringpneumococcalconjugatevaccineimpactinlowresourcesettings AT phetsouvanhr evaluationstrategiesformeasuringpneumococcalconjugatevaccineimpactinlowresourcesettings AT dattass evaluationstrategiesformeasuringpneumococcalconjugatevaccineimpactinlowresourcesettings AT foxk evaluationstrategiesformeasuringpneumococcalconjugatevaccineimpactinlowresourcesettings AT newtonpn evaluationstrategiesformeasuringpneumococcalconjugatevaccineimpactinlowresourcesettings AT mulhollandke evaluationstrategiesformeasuringpneumococcalconjugatevaccineimpactinlowresourcesettings AT nguyencd evaluationstrategiesformeasuringpneumococcalconjugatevaccineimpactinlowresourcesettings AT dancedab evaluationstrategiesformeasuringpneumococcalconjugatevaccineimpactinlowresourcesettings AT satzkec evaluationstrategiesformeasuringpneumococcalconjugatevaccineimpactinlowresourcesettings AT russellfm evaluationstrategiesformeasuringpneumococcalconjugatevaccineimpactinlowresourcesettings |